Growth hormone-releasing hormone analogue
Sermorelin
Sermorelin's half-life is about 10 minutes in the app; the label text gives 11-12 minutes after intravenous or subcutaneous doses and a subcutaneous bioavailability of about 6%.1
Sermorelin after one dose: 50% at ~10 min, 25% at 20 min, 12.5% at 30 min.
Drawn from the half-life in the app's model, ~10 min. The model's figures
- Compound
- Sermorelin
- Symbol
- SER
- Family
- Growth hormone peptides
- Parts
- 14
- References
- 19
- Checked
- Last reviewed . Sources are listed below.
Overview
Sermorelin is an amidated 29 amino acid peptide that corresponds to the amino-terminal segment of the 44 amino acid residues of human growth hormone-releasing hormone (GHRH or GRF), according to the label text.1 Prakash and Goa of Adis International, writing in BioDrugs in 1999, call it "the shortest synthetic peptide with full biological activity of GHRH".2
FDA's 2013 notice states that Geref (sermorelin acetate) injection 0.05 mg per ampoule was initially approved on 28 December 1990, for evaluating the ability of the pituitary somatotroph to secrete growth hormone, and that the 0.5 mg and 1.0 mg vials were initially approved on 26 September 1997 for idiopathic growth hormone deficiency in children with growth failure.3 EMD Serono notified FDA in 2008 that the products were being discontinued, FDA withdrew the approvals effective 18 June 2009, and FDA determined in 2013 that they "were not withdrawn from sale for reasons of safety or effectiveness".3 The WADA 2026 Prohibited List names sermorelin among the growth hormone-releasing hormone analogues prohibited at all times.4
The human studies cited here are trials of GHRH(1-29) by injection in children with growth failure and in older adults between 1987 and 1997, plus pharmacokinetic work in healthy men. The row of figures at the top is the app's; where the label text or a study gives a different figure, it is set beside the app's below.1,5,6
How it works
In people
The label text states that sermorelin acetate for injection "increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH", and that it is similar to the native 44 amino acid hormone "in its ability to stimulate GH secretion in humans".1 Prakash and Goa write that intravenous and subcutaneous sermorelin "specifically stimulate growth hormone secretion from the anterior pituitary".2
In 11 healthy men aged 64 to 76, Vittone and colleagues found that nightly 2 mg subcutaneous injections of GHRH(1-29) for 6 weeks increased mean nocturnal GH release and GH peak amplitude "with no change in GH pulse frequency or in levels of IGF-I, IGFBP-3, or GHBP".7 Khorram and colleagues, giving the analogue [Nle27]GHRH-(1-29)-NH2 nightly to men and women aged 55 to 71, report "an acute release of GH, which lasted for 2 h".8
Walker, in an editorial in Clinical Interventions in Aging in 2006, writes that sermorelin's effects are "regulated by negative feedback involving the inhibitory neurohormone, somatostatin".9 The editorial reports no data, and states that the Society for Applied Research in Aging, with which Walker is affiliated, would provide sermorelin free of cost to practitioners willing to study it.9
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~10 min
- Bioavailability
- 95%
- Typical dose
- 200–500 mcg/day
- Route
- SubQ
- Time to peak
- ~10 min
The app lists a half-life of about 10 minutes, a bioavailability of 95% and a time to peak of about 10 minutes. The figures reported in the label text and the studies differ, as the table shows.1
| Parameter | App's figure | Reported in the sources cited |
|---|---|---|
| Half-life | About 10 minutes | The label text gives "11-12 minutes after either intravenous or subcutaneous administration".1 The Irish Medicines Board's 2006 summary of product characteristics for Geref 50 gives sermorelin a plasma half life of 6-7 minutes after intravenous administration.5 Soule and colleagues of the University of Cape Town report a disappearance half-time of 4.3 +/- 1.4 min for GHRH-(1-29)-NH2 in 10 normal men given a 90-minute intravenous infusion.6 |
| Bioavailability | 95% | The label text states "The mean absolute bioavailability after SC administration is about 6%".1 In anaesthetized rats the total reaching the circulation after subcutaneous injection was "only 4% of that obtained after i.v. administration".10 None of the summary texts of the sources cited reports 95%. |
| Time to peak | About 10 minutes | The label text states that after 2 mg subcutaneously in 12 normal volunteers "peak concentrations of sermorelin were reached in 5-20 minutes".1 The 2006 Irish summary states that after an intravenous dose the peak response "is reached approximately 30 minutes (15-60) post dose and lasts 2-3 hours".5 |
| Duration of activity | About 1 hour | The Irish summary gives a response that "lasts 2-3 hours", and Wilton and colleagues of Kabi Pharmacia Peptide Hormones report GH levels "elevated for about 3 hours" in 30 healthy men although the peptide "was rapidly eliminated after intravenous injection".5,11 |
The chart below is an illustration from a one-compartment model with the app's half-life of about 10 minutes and time to peak of about 10 minutes. Its once-daily option is the bedtime schedule of Thorner and colleagues' children's trial and its twice-daily option that of Corpas and colleagues; its doses are in mcg and are not those trials' doses.12,13
Human studies
A query of PubMed on 16 November 2026 for sermorelin returned 334 records. The studies below come from the titles and summary texts read from that query and from a second query on GHRH(1-29) in elderly people; records not read are not covered. Most of the studies name the molecule GHRH(1-29) or GHRH(1-29)NH2 rather than sermorelin, and the summary texts name no funder.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ross and colleagues, 198714 | Treated with GHRH(1-29)NH2, no comparator stated | 18 prepubertal GH-deficient children | Twice daily subcutaneously; 6 to 18 months in the 8 responders | Height velocity rose in 12 of 18 and 8 had a worthwhile response (above 2 cm/yr); 4 of 14 previously treated with hGH had growth deceleration for unknown reasons; anti-GHRH antibodies in 14 patients, without apparent effect on growth |
| Thorner and colleagues, 199612 | Multicenter open-label study | 110 untreated prepubertal GH-deficient children; 86 eligible for efficacy analysis | 30 micrograms/kg/day subcutaneously at bedtime, up to 1 year | Height velocity 4.1 +/- 0.9 cm/yr at baseline, 8.0 +/- 1.5 at 6 months, 7.2 +/- 1.3 at 12 months; 74% good responders at 6 months; no adverse biochemical or hormonal changes |
| Kirk and colleagues, 199415 | Treated for 12 months, then follow-up off therapy; no comparator stated | 18 pre-pubertal children with idiopathic short stature; 1 withdrawn as non-compliant | 20 micrograms/kg twice daily subcutaneously for 1 year | Height velocity 4.8 (SD 0.9) cm/yr before and 7.2 (SD 1.6) at 12 months (P = 0.001); overnight GH levels and GH responses to GHRH testing fell; fasting glucose, insulin and IGF-I rose; catch-down growth after stopping |
| Grunt and colleagues, 199516 | Seven children treated, no comparator | 7 children with idiopathic short stature and normal GH levels | 30 micrograms/kg/day for 12 months (2 children) or 24 months (5) | The authors conclude that some patients grow well during the first 2 years; therapy was discontinued if growth did not rise by more than 2.0 cm/year over the pre-therapy rate, and it was discontinued in 2 of 7 at 12 months |
| Corpas and colleagues, 199213 | Crossover of two doses in random order, 14-day washout | 10 healthy old men (mean age 68.0); 9 young men (26.2) as baseline comparison | 0.5 mg and 1 mg subcutaneously twice daily, 14 days each | Dose-related rises in GH and IGF-I, significant only at 1 mg; no significant difference from young men after 1 mg; glucose, blood pressure and chemistry unchanged, phosphate rose |
| Vittone and colleagues, 19977 | Before and after 6 weeks, treated at home; no placebo group described | 11 healthy non-obese men aged 64 to 76 with low IGF-I | 2 mg subcutaneously every night, 6 weeks | Nocturnal GH release, GH peak area and amplitude rose; IGF-I, body composition, glucose and insulin did not change; 2 of 6 strength measures and 1 endurance test improved; no significant adverse effects |
| Khorram and colleagues, 1997 (analogue [Nle27]GHRH-(1-29)-NH2)8 | Single-blind: 4 weeks placebo, then 16 weeks of the analogue | 10 women and 9 men aged 55 to 71 | 10 microg/kg subcutaneously every night, 16 weeks | Nocturnal GH (P < 0.01 women, P < 0.05 men), IGF-I and IGFBP-3 rose; skin thickness rose in both sexes; lean body mass and insulin sensitivity rose in men only, as did general well-being and libido; sleep quality unaffected; the only adverse side-effect was transient hyperlipidemia |
Prakash and Goa's review concludes that "Limited data indicate that once daily subcutaneous sermorelin 30 microg/kg bodyweight given at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency" and that "The effects of the recommended dosage of sermorelin have not been directly compared with those of somatropin".2 For sermorelin at 30 microg/kg bodyweight per day "given as continuous infusion or as 3 divided doses", the increases in height velocity from baseline "were less than those in children receiving once daily subcutaneous somatropin 30 microg/kg bodyweight", and the effect on final adult height "is yet to be determined".2
Deeper analysis: Thorner and colleagues, 1996
Thorner of the University of Virginia and colleagues of the Geref International Study Group treated 110 untreated prepubertal GH-deficient children with 30 micrograms/kg of GHRH-(1-29) at bedtime for up to a year, in a multicenter open-label study in the Journal of Clinical Endocrinology and Metabolism.12 The authors conclude that the dose "was effective in increasing height velocity in GH-deficient children" and that "overall GHRH was well tolerated".12 The study group carries the product's brand name, Geref, and the Federal Register notice names EMD Serono as the holder of the application, but the PubMed record states no funder, gives no author ties to a sponsor and does not state the authors' own limitations.12,3
Deeper analysis: Corpas and colleagues, 1992
Corpas and colleagues of the National Institute on Aging at the National Institutes of Health gave old men 0.5 mg and 1 mg GHRH-(1-29) subcutaneously twice daily for 14 days each, in random order with a 14-day gap, and compared them with 9 young men.13 Mean 24-hour GH, area under the peaks, peak amplitude and IGF-I rose "only at the high dose", and after it there were "no significant differences" from the young men on these parameters.13 The authors write that the results suggest "that prolonged treatment could improve age-related alterations in body composition", a hypothesis, since the summary text reports no body composition measurements; it states no funder and no limitations.13
Deeper analysis: Vittone and colleagues, 1997
Vittone and colleagues of the Johns Hopkins University School of Medicine gave 11 healthy men aged 64 to 76 with low baseline IGF-I a nightly 2 mg subcutaneous injection of GHRH for 6 weeks, and measured GH every 20 minutes overnight, IGF-I, muscle strength, body composition and glucose tolerance before and after.7 Mean nocturnal GH release and GH peak amplitude rose while IGF-I did not, and weight, DEXA measures of muscle and fat, glucose, insulin and lipids did not change.7 Two of six measures of muscle strength (upright row, P < .02, and shoulder press, P < .04) and one test of muscle endurance (abdominal crunch, P < .03) improved.7 The authors write that "These data suggest that single nightly doses of GHRH are less effective than multiple daily doses of GHRH in eliciting GH- and/or IGF-I-mediated effects" and that "GHRH treatment may increase muscle strength".7 The summary text describes no placebo group and states no funder.7
Doses reported in studies and on labels
The app lists a typical dose of 200 to 500 mcg a day by subcutaneous injection, which is the app's figure. The label text reproduced by RxList gives 0.2 to 0.3 mg once daily at bedtime, which is 200 to 300 mcg, and prints the unit as mcg in one section and mg in another; the paediatric studies dose by body weight and the adult studies used 0.5 mg, 1 mg or 2 mg per injection (Corpas, Vittone) or 10 microg/kg (Khorram, analogue).1,12,13,7,8
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Label text, as reproduced by RxList (FDA revision date 2 October 2001)1 | 0.2 to 0.3 mg in the summary of the page and "0.2 - 0.3 mcg" in its dosage section | Once daily at bedtime, subcutaneous | No length given |
| Thorner, 1996 (GH-deficient children)12 | 30 micrograms/kg a day | Once daily at bedtime, subcutaneous | Up to 1 year |
| Corpas, 1992 (old men)13 | 0.5 mg and 1 mg | Twice daily, subcutaneous | 14 days each |
| Vittone, 1997 (older men)7 | 2 mg | Nightly, subcutaneous | 6 weeks |
| Khorram, 1997 (older men and women, analogue)8 | 10 microg/kg | Nightly, subcutaneous | 16 weeks |
| Geref 50 summary of product characteristics, 2006 (pituitary function test)5 | 1.0 microgram/kg intravenously; each ampoule holds 50 micrograms | Single injection | One test |
Side effects reported
The label text states that "The most common treatment-related adverse event (occurring in about 1 patient in 6) is local injection reaction characterized by pain, swelling or redness", and that of 350 patients exposed in clinical trials, "three discontinued therapy due to injection reactions".1 Other treatment-related events each occurred in under 1%: "headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria".1 It also states that "A large proportion of patients develop" anti-GRF antibodies at least once during treatment, that their significance is not clear, that "often a positive test at one growth assessment will become negative by the next assessment", and that "The presence of antibodies does not appear to affect growth or appear to be related to a specific adverse reaction profile".1 For hypothyroidism it states that "In clinical studies, the incidence of hypothyroidism during Sermorelin therapy was 6.5%", and that in the largest clinical study "8 of 110 enrolled patients were on thyroid replacement therapy prior to Sermorelin therapy and an additional 5 after initiating therapy".1
With intravenous diagnostic use, the label text lists "flushing of the face, injection site pain, redness and/or swelling, nausea, headache, vomiting, dysgeusia, pallor and tightness in the chest".1 The Geref 50 summary of 2006 states that "Facial heat, facial flush and injection site pain occasionally occur and usually disappear within a few minutes".5
Ross and colleagues report anti-GHRH antibodies in 14 of 18 children and growth deceleration on GHRH in 4 of 14 previously treated with growth hormone, for unknown reasons.14 Prakash and Goa write that "Transient facial flushing and pain at injection site were the most commonly reported adverse events".2 Corpas and colleagues report that fasting glucose, blood pressure and chemistry and hematology profiles were unaffected, Vittone and colleagues that "No significant adverse effects were observed", and Khorram and colleagues, studying the analogue, that "The only adverse side-effect was transient hyperlipidemia, which resolved by the end of the study".13,7,8
The label text states that long-term animal studies of carcinogenicity and fertility have not been performed, that rats and rabbits given 0.5 mg/kg/day had fetuses with "minor variations", and that there are no adequate and well controlled studies in pregnant women.1 Dominikowski and colleagues' 2026 table lists "No long term safety data available" for sermorelin.17
Bloodwork and markers
The app lists IGF-1, blood glucose and insulin as markers. Results differ by study: Thorner and colleagues report no change in fasting glucose and no "excessive generation of insulin-like growth factor I" in children, Kirk and colleagues report that fasting glucose, insulin and IGF-I increased during therapy, and Vittone and colleagues report no change in IGF-I, glucose or insulin after 6 weeks in older men.12,15,7
The label text states that serum levels of inorganic phosphorus, alkaline phosphatase, GH and IGF-1 may increase with treatment, and that it calls for thyroid hormone determinations before and during therapy because untreated hypothyroidism can jeopardize the response.1 It also states that concomitant glucocorticoid therapy may inhibit the response.1
Regulatory and anti-doping status
| Body and document | What it says about sermorelin | Scope |
|---|---|---|
| FDA, Federal Register notice, 4 March 20133 | Geref 0.5 mg and 1.0 mg vials (NDA 20-443, EMD Serono, approved 26 September 1997) and 0.05 mg ampoules (NDA 19-863, approved 28 December 1990) "were not withdrawn from sale for reasons of safety or effectiveness", and abbreviated applications that refer to them may be approved if all other requirements are met | United States, discontinued Geref products |
| FDA, 503B bulk drug substances list, updated 21 March 202518 | Sermorelin Acetate is listed in "503B Category 1: Bulk Drug Substances Under Evaluation", marked with two asterisks, which the list uses for "Bulk drug substances in category 1 that are components of FDA-approved drugs" | Outsourcing facilities, United States |
| FDA, 503A bulk drug substances list, updated 14 May 202619 | The text of the list does not contain the word sermorelin | Pharmacy compounding, United States |
| Irish Medicines Board, Geref 50 summary of product characteristics, 20065 | Indicated "For the evaluation of the functional capacity and response of the somatotrophs of the anterior pituitary"; contraindicated in hypersensitivity and "during pregnancy or lactation" | Ireland, diagnostic ampoule |
| WADA Prohibited List 20264 | Names "growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)" under S2, a class prohibited at all times | In and out of competition |
The label text states that sermorelin "is approved for diagnostic evaluation of pituitary function and also for increasing growth in children", and the RxList page carrying it states "Sermorelin acetate is discontinued; generic versions may be available".1 The app's note describes sermorelin as previously approved as a diagnostic agent; FDA's 2013 notice also records the approval of the 0.5 mg and 1.0 mg vials for children's growth failure.3
Storage and handling
Sources in this part
What is not known
Dominikowski and colleagues write in Frontiers in Endocrinology in 2026 that "clinically meaningful benefits in healthy individuals remain uncertain because the human evidence base is limited and largely indirect".17 The journal's funding statement says the research received no external funding, that the article processing charge was partially funded by a Poznan university foundation that "was not involved in the manuscript", and that no conflicts were declared. Its generative AI statement says Perplexity (Gemini Pro 3.1 engine), ChatGPT (version 5.4) and Claude were used "solely to assist with language editing and initial literature screening".17 The adult trials of Corpas and colleagues and Vittone and colleagues enrolled 10 and 11 older men and treated them for 14 days and 6 weeks.13,7
The label text states that "No metabolism studies have been performed in humans", that for renal and hepatic insufficiency "No data are available", and that patients with growth hormone deficiency secondary to an intracranial lesion "were not studied in clinical trials".1 Prakash and Goa state that the effect of long-term treatment on final adult height "is yet to be determined".2 Among the summary texts of the sources cited, the longest trial of GHRH(1-29) itself in older adults lasted 6 weeks (Vittone and colleagues); the 16-week trial of Khorram and colleagues used the analogue.7,8
Frequently asked questions
What is the half-life of sermorelin?
The label text gives a half-life of 11-12 minutes after either intravenous or subcutaneous administration, and the app lists about 10 minutes.1 The 2006 Irish summary gives 6-7 minutes after intravenous administration, and Soule and colleagues report a disappearance half-time of 4.3 +/- 1.4 min in 10 normal men.5,6
What is sermorelin?
What is the bioavailability of sermorelin?
The label text gives a mean absolute bioavailability of about 6% after subcutaneous administration, and the app lists 95%.1
How long does sermorelin take to peak?
Is sermorelin FDA approved?
Sermorelin acetate was approved by FDA as Geref in 1990 for evaluating pituitary growth hormone secretion and in 1997 for idiopathic growth hormone deficiency in children with growth failure, and the approvals were withdrawn effective 18 June 2009 after EMD Serono discontinued the products.3
Is sermorelin banned by WADA?
Yes: the WADA 2026 Prohibited List names sermorelin as an example of the growth hormone-releasing hormone analogues in S2, a class prohibited at all times, in and out of competition.4
Why was Geref (sermorelin) discontinued?
FDA's 2013 notice states that Geref was not withdrawn from sale for reasons of safety or effectiveness, after EMD Serono notified FDA in 2008 that it was being discontinued.3 Walker's 2006 editorial, by an author affiliated with a society that offers sermorelin to practitioners for study, writes that sermorelin "could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer".9
What side effects were reported with sermorelin?
The label text states that the most common treatment-related adverse event, in about 1 patient in 6, was a local injection reaction of pain, swelling or redness, and that 3 of 350 patients exposed in clinical trials discontinued because of injection reactions.1 Other treatment-related events each occurred in under 1%.1 For intravenous diagnostic use, the label text lists reactions including "flushing of the face", nausea, headache and vomiting.1
What doses of sermorelin were used in studies?
Children's trials gave 20 to 30 micrograms/kg subcutaneously, once or twice daily, and adult trials gave 0.5 mg and 1 mg twice daily for 14 days or 2 mg nightly for 6 weeks, and the analogue trial of Khorram and colleagues gave 10 microg/kg nightly for 16 weeks.12,15,13,7,8 The RxList page gives 0.2 - 0.3 mg in its summary and 0.2 - 0.3 mcg in the label's dosage section, and the app lists 200 to 500 mcg a day.1
Guides, tools and comparisons
- Sermorelin dosageA guide that answers a question on this compound.
- Calculator for SermorelinA calculator set up for this compound.
- Sermorelin vs tesamorelinA side-by-side with another compound.
- Ipamorelin vs sermorelinA side-by-side with another compound.
- Previous in Growth hormone peptides: PEG-MGF (Pegylated Mechano Growth Factor)The compound before this one in the class.
- Next in Growth hormone peptides: Sermorelin + IpamorelinThe compound after this one in the class.
References
- Sermorelin acetate (Geref) prescribing information as reproduced by RxList; the page gives an FDA revision date of 2 October 2001. RxList label text
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. PMID 18031173
- Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register 2013;78(42):14095-14096. Federal Register 2013-04827
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026 list
- Irish Medicines Board. Summary of Product Characteristics: Geref 50 (sermorelin acetate), printed 13 July 2006. HPRA Geref 50 SmPC
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab 1994. PMID 7962295
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997. PMID 9005976
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006. PMC2699646
- Rafferty B, et al. Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J Endocrinol 1985. PMID 2866222
- Wilton P, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl 1993. PMID 8329825
- Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab 1996. PMID 8772599
- Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992. PMID 1379256
- Ross RJ, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet 1987. PMID 2879138
- Kirk JM, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf) 1994. PMID 7955460
- Grunt JA, et al. Effects of long-term growth hormone releasing hormone 1-29 in significantly short children. Acta Paediatr 1995. PMID 7670244
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
- Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act, updated 21 March 2025. FDA 503B categories
- Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated 14 May 2026. FDA 503A categories